Chemours Company (CC) shares plummeted 12.79% in after-hours trading on Thursday, following the release of disappointing fourth-quarter and full-year 2025 financial results that fell short of analyst expectations.

The chemical company reported Q4 adjusted earnings per share of $0.05, missing the consensus estimate of $0.07 by 26.47%. Quarterly sales of $1.300 billion also came in below the estimated $1.328 billion. More significantly, the company's net loss attributable to shareholders widened to $47 million, a substantial increase from the $11 million loss reported a year earlier.

The earnings miss was driven by volume declines in Chemours' titanium technologies and advanced performance materials businesses, which the company attributed to weaker cyclically-sensitive end markets. The wider loss was also impacted by a non-cash inventory charge and less favorable product mix in the advanced performance materials segment. For the full year, adjusted EPS of $0.95 slightly missed the $0.96 estimate, while adjusted EBITDA of $742 million came in below the $755.2 million forecast.